Chengdu Di’ao Pharmaceutical Group

Chengdu Di'ao Pharmaceutical Group is a prominent Chinese pharmaceutical enterprise established in 1988 as a high-tech entity under the Chinese Academy of Sciences. The company specializes in the research, development, and large-scale manufacturing of cardiovascular medicines, traditional Chinese medicines (TCM), and chemical drugs. Its flagship product, Di'ao Xinxuekang Capsules, is a leading treatment for coronary heart disease in China and achieved a significant milestone as the first TCM to obtain marketing authorization in the European Union. The group operates multiple specialized subsidiaries and research institutes, focusing on therapeutic areas such as cardiology, endocrinology, and immunology.